Health Canada

Health Canada

January 14, 2014 13:45 ET

Health Canada: Note to Editors

OTTAWA, ONTARIO--(Marketwired - Jan. 14, 2014) - Health Canada today released the January 2014 issue of the Canadian Adverse Reaction Newsletter (CARN).

This issue includes an article on a class of cancer drugs known as VEGF receptor inhibitors, which are used to inhibit tumour cell growth, and the risk of a serious blood clotting disorder known as thrombotic microangiopathy (TMA).

It also includes an article on a potential increased risk of complications when Durepair Dura Regeneration Matrix, a collagen graft used for membrane repair in neurosurgery, is used with other products used to close or seal wounds.

The edition also contains a quarterly summary of health professional and consumer advisories.

The January 2014 edition of CARN is available on Health Canada's website at: www.healthcanada.gc.ca/carn.

Contact Information

  • Media Inquiries:
    Media Relations
    Health Canada
    613-957-2983